Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis

Autoři: Yuan Li aff001;  Hairong Huang aff003;  Weijie Dong aff002;  Tinglong Lan aff002;  Jun Fan aff002;  Shu’an Wen aff003;  Tingting Zhang aff003;  Shibing Qin aff002;  Ai Guo aff001
Působiště autorů: Department of Orthopedics, Beijing Friendship Hospital, Capital Medical University, Beijing, China aff001;  Department of Orthopedics, Beijing Chest Hospital, Capital Medical University, Beijing, China aff002;  National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China aff003
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article



Linezolid has shown strong antimicrobial activity against multidrug-resistant (MDR)/rifampin-resistant strains of Mycobacterium tuberculosis. Linezolid achieves clinical efficacy mainly through area under the concentration time curve/minimum inhibitory concentration ratio in the infected lesion site. Previous studies mainly focused on the relationship between linezolid concentrations in the blood and infected bone tissue when the blood drug concentration reached the peak 2 h after administration. However, we do not know whether linezolid can maintain the same bone/plasma ratio in infected bone tissue when the blood concentration reaches the trough level. Therefore, this study aimed to evaluate the penetrability of linezolid into bone tissue 24 h after administration in patients with MDR spinal tuberculosis (TB).


Nine MDR spinal TB patients, who received a treatment regimen including linezolid and underwent surgery, were enrolled prospectively from April 2017 to March 2019. Blood and diseased bone tissue specimens were collected simultaneously during operations 24 h after taking 600 mg of linezolid orally. Linezolid concentrations in plasma and diseased bone tissue specimens were determined by high-performance liquid chromatography–tandem mass spectrometry.


Following a 600 mg oral administration of linezolid 24 h before surgery, median concentrations of linezolid in plasma and diseased bone tissue for the 9 patients were 1.98 mg/L (range 0.30–3.44 mg/L) and 0.60 mg/L (range 0.18–2.13 mg/L), respectively, at resection time. The median diseased bone/plasma linezolid concentration ratio was 0.48 (range 0.30–0.67). Pearson’s correlation analysis showed that linezolid concentrations in the plasma were positively related to those in diseased bone tissue (r = 0.949, p < 0.001).


After 24 h of medication, linezolid still had good penetrability into diseased bone tissue in patients with MDR spinal TB.

Klíčová slova:

Blood – Blood plasma – Drug administration – Lesions – Surgical and invasive medical procedures – Surgical resection – Tuberculosis


1. Word Health Organization. Global tuberculosis report 2018. Geneva, Switzerland: Word Health Organization, 2018.

2. Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.Ann Clin Microbiol Antimicrob. 2016,15(1):41. doi: 10.1186/s12941-016-0156-y 27334498

3. Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.Eur Respir J. 2015,45(1):161–70. doi: 10.1183/09031936.00035114 25234807

4. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al.Linezolid for treatment of chronic extensively drug-resistant tuberculosis.N Engl J Med. 2012,367(16):1508–18. doi: 10.1056/NEJMoa1201964 23075177

5. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.Eur Respir J. 2009,34(2):387–93. doi: 10.1183/09031936.00009509 19282348

6. Word Health Organization.WHO treatment guidelines for multidrug-and rifampicin-resistant tuberculosis, 2018 update. Geneva: Word Health Organization.

7. McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, et al. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2009,53(9):3981–4. doi: 10.1128/AAC.01378-08 19564361

8. Lovering AM, Zhang J, Bannister GC, Lankester BJ, Brown JH, Narendra G, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother. 2002,50(1):73–77. doi: 10.1093/jac/dkf066 12096009

9. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother. 2002,50(5):747–750. doi: 10.1093/jac/dkf207 12407135

10. Kutscha-Lissberg F, Hebler U, Muhr G, Köller M. Linezolid penatration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2003,47(12):3964–3966. doi: 10.1128/AAC.47.12.3964-3966.2003 14638510

11. Word Health Organization.WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update, Geneva: World Health Organization; 2016.

12. Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;3:CD012836. doi: 10.1002/14651858.CD012836.pub2 30893466

13. Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, et al. Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.EBioMedicine. 2015,2(11):1627–33. doi: 10.1016/j.ebiom.2015.09.051 26870788

14. Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, et al. Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.Clin Infect Dis. 2018,67(suppl_3):S327–S335. doi: 10.1093/cid/ciy625 30496467

15. Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolidcontaining regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.J Thorac Dis. 2015,7(4):603–15. doi: 10.3978/j.issn.2072-1439.2015.03.10 25973226

16. Srivastava S, Magombedze G, Koeuth T, Sherman C, Pasipanodya JG, Raj P, et al. Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.Antimicrob Agents Chemother. 2017,61(8). pii: e00751–17. doi: 10.1128/AAC.00751-17 28584143

17. Cattaneo D, Alffenaar JW, Neely M. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.Expert Opin Drug Metab Toxicol. 2016,12(5):533–44. doi: 10.1517/17425255.2016.1166204 26982718

18. Traunmüller F, Schintler MV, Spendel S, Popovic M, Mauric O, Scharnagl E, et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabeticpatients with bacterial foot infections. Int J Antimicrob Agents. 2010,36(1):84–6. doi: 10.1016/j.ijantimicag.2010.03.007 20456925

19. Schon T, Jureen P, Chryssanthou E, Giske CG, Sturegård E, Kahlmeter G, et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011,15:502–509. doi: 10.5588/ijtld.10.0238 21396210

20. Rodriguez JC, Cebrian L, Lopez M, Ruiz M, Jiménez I, Royo G. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004,53:441–444. doi: 10.1093/jac/dkh119 14963069

21. Nuermberger E. Evolving strategies for dose optimization of linezolid for treatment of tuberculosis. Int J Tuberc Lung Dis. 2016,20(12):48–51. doi: 10.5588/ijtld.16.0113 28240573

22. Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, et al. A comparison of linezolid lung tissue concentrations among patients with drug- resistanttuberculosis. Eur Respir J. 2018,51(2).

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden